Valeant Reports 41% Increase in Second-Quarter Revenue
Valeant Pharmaceuticals International Inc. (VRX) raised its forecast for full-year earnings after posting a 41 percent increase in second-quarter revenue.
Valeant estimates 2013 adjusted earnings per share of $6 to $6.20, up from a prediction in May of $5.55 to $5.85. Second-quarter revenue excluding one-time items rose to $1.1 billion, the company said today in a statement.
Cash earnings per share increased 54 percent, excluding one-time items, in the second-quarter to $1.34, the company said. Analysts had estimated an EPS of $1.28, according to a survey compiled by Bloomberg.
To contact the reporter on this story: Tim Farrand in Edinburgh at firstname.lastname@example.org
To contact the editor responsible for this story: David Risser at email@example.com